Popular on EntSun
- Jazz Fusion Legend Bob Holz To Release Album With Larry Coryell - 348
- Bald Guy Greetings Launches Bold New Postcard Line Celebrating Over-the Top (and Often Delusional) Confidence - 138
- Tec-Masters to Support In-Space Testing of Honda Regenerative Fuel Cell Technology on the International Space Station - 121
- Retirement Income Specialist Daniel Rondberg Joins Tom Hegna on the Exciting New Season of "Financial Freedom with Tom Hegna" - 115
- LIB Large-Scale Walk-In Test Chamber Full Process Delivery: MIL-STD-810H Chambers Enable Extreme Environment Testing - 105
- The Villages Welcomes NexGen Laser Pain and Rehab Centers—Revolutionizing Pain Management with MLS Laser Technology - 105
- Food Logistics Names Puga Sankara Founder CEO of Smart Gladiator LoadProof as Recipient of 2025 Rock Stars of the Supply Chain Award
- Family Estrangement on the Rise: Therapist Offers Support, Perspective, and Community for Those Affected
- DTFPrinter.com Launches to Revolutionize the Custom Transfer Printing Experience for Crafters and Creators
- OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges
Similar on EntSun
- K2 Integrity and Sonata One Partner to Accelerate Capital Raising, Reduce Risk, and Deliver Scalable Advisory Services for Private Fund Managers
- Kemeny, Ramp & Renaud, LLC Welcomes Prominent Trusts and Estates Attorney Gary B. Cornick to Its Firm
- Electives Appoints DraftKings' CPO Linda Aiello to Board Amid Record Quarter
- Co-Creating the Future of ePaper: ZKONG and E Ink at Touch Taiwan 2025
- Webinar Announcement: Mexico's Evolving AML/CFT Environment: FATF Review and FTO Designations
- Emerging Managers Podcast Launches, Highlighting New Players in Venture Capital Outperforming the Status Quo
- Home Run Pest & Termite Control Launches Monthly Mosquito Service to Help Wylie, Plano, and Rockwall Homeowners Reclaim Their Backyards
- T&S and US Conec Ink Global Licensing Deal on MDC Technology to Advance High-Density Optical Interconnects
- Coming Up on "Financial Freedom with Tom Hegna" Retirement Authority Daniel Rondberg from Nation's First Financial
- The Ten News Wins 2025 Ambie Award for Best News Podcast
GlycoNex Presents Preclinical Data on GNX1021 at AACR Annual Meeting 2025
EntSun News/11057275
Novel glycan-directed ADC shows preclinical activity in gastric cancer and potential to address underserved patient population
NEW TAIPEI CITY, Taiwan, April 28, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced the presentation of preclinical data on GNX1021, its lead antibody-drug conjugate (ADC) program, at the American Association for Cancer Research (AACR) Annual Meeting 2025. The presentation is part of a poster session held on April 28, 2025, at McCormick Place in Chicago.
GNX1021 is a novel ADC that targets branched Lewis B/Y (bLeB/Y), a tumor-associated glycan highly expressed in gastric cancer and other solid tumors. The target has a distinct expression profile compared to HER2 and CLDN18—two well-known markers in gastric cancer—allowing GNX1021 to potentially treat patients who are not eligible for current HER2- or CLDN18-targeted therapies.
The poster presents preclinical data showing GNX1021's antitumor activity in gastric cancer models with high bLeB/Y expression, along with a favorable safety profile in nonclinical studies. Findings suggest that GNX1021 may offer a differentiated therapeutic option for gastric cancer patients with limited targeted treatment choices.
More on EntSun News
"These data demonstrate the potential of GNX1021 to expand the treatment landscape for gastric cancer by targeting a glycan biomarker not addressed by existing therapies," said Dr. Mei-Chun Yang, CEO of GlycoNex. "As a first-in-class anti-glycan ADC, GNX1021 exemplifies our approach to developing next-generation oncology therapeutics designed to overcome tumor heterogeneity and drug resistance."
GlycoNex is advancing GNX1021 through IND-enabling preclinical development, with an IND submission planned for Q1 2026 and Phase 1 trial initiation expected in Q2 2026.
Presentation Details:
About GlycoNex Inc.
GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit http://www.glyconex.com.tw.
Contacts for GlycoNex, Inc.
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
[email protected]
Media Relations
Eric Reiss
[email protected]
SOURCE GlycoNex, Inc.
NEW TAIPEI CITY, Taiwan, April 28, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced the presentation of preclinical data on GNX1021, its lead antibody-drug conjugate (ADC) program, at the American Association for Cancer Research (AACR) Annual Meeting 2025. The presentation is part of a poster session held on April 28, 2025, at McCormick Place in Chicago.
GNX1021 is a novel ADC that targets branched Lewis B/Y (bLeB/Y), a tumor-associated glycan highly expressed in gastric cancer and other solid tumors. The target has a distinct expression profile compared to HER2 and CLDN18—two well-known markers in gastric cancer—allowing GNX1021 to potentially treat patients who are not eligible for current HER2- or CLDN18-targeted therapies.
The poster presents preclinical data showing GNX1021's antitumor activity in gastric cancer models with high bLeB/Y expression, along with a favorable safety profile in nonclinical studies. Findings suggest that GNX1021 may offer a differentiated therapeutic option for gastric cancer patients with limited targeted treatment choices.
More on EntSun News
- Twitter's Buzzing! What's the Deal with PhotoG, the AI Everyone's Talking About?
- New WHO Mental Health Guidelines Condemn Coercive Psychiatry
- Keenan's Caring Konnections, LLC
- Celebrate Children's Day in Tochigi City!
- Mensa identifies best board games of 2025
"These data demonstrate the potential of GNX1021 to expand the treatment landscape for gastric cancer by targeting a glycan biomarker not addressed by existing therapies," said Dr. Mei-Chun Yang, CEO of GlycoNex. "As a first-in-class anti-glycan ADC, GNX1021 exemplifies our approach to developing next-generation oncology therapeutics designed to overcome tumor heterogeneity and drug resistance."
GlycoNex is advancing GNX1021 through IND-enabling preclinical development, with an IND submission planned for Q1 2026 and Phase 1 trial initiation expected in Q2 2026.
Presentation Details:
Event: | American Association for Cancer Research (AACR) Annual Meeting 2025 |
Session Category: | Experimental and Molecular Therapeutics |
Session: | Growth Factor Receptors and Other Surface Antigens as Targets for Therapy 1 |
Abstract Title: (#2932) | GNX1021, a novel ADC targeting glycans with branched Lewis B/Y, demonstrated preclinical tumor control activity in gastric cancer models and favorable safety |
Date and Time: | April 28, 2025; 2:00 pm CDT |
More on EntSun News
Location: | McCormick Place Convention Center, Chicago Poster Section 17, Poster Board 6 |
About GlycoNex Inc.
GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit http://www.glyconex.com.tw.
Contacts for GlycoNex, Inc.
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
[email protected]
Media Relations
Eric Reiss
[email protected]
SOURCE GlycoNex, Inc.
Filed Under: Business
0 Comments
Latest on EntSun News
- NaturismRE Launches the 11 Levels of Naturism: A Groundbreaking Framework Guiding the Global Naturist Journey
- K2 Integrity and Sonata One Partner to Accelerate Capital Raising, Reduce Risk, and Deliver Scalable Advisory Services for Private Fund Managers
- The World's No.1 Superstar™ Walks Where Legends Rest: A Sacred Encounter in Rome Before the Pope's Passing
- Coming Up on "Financial Freedom with Tom Hegna" Financial Expert Parker Faulkner
- Tobu Railway Announces a Price Revision on the "NIKKO PASS All Area" and "NIKKO PASS World Heritage Area," from April 20, 2025
- Kemeny, Ramp & Renaud, LLC Welcomes Prominent Trusts and Estates Attorney Gary B. Cornick to Its Firm
- DESERT BLOOM™ Makes a Bold Entrance, Kicking Fast Fashion Off Its High Horse with Earth Day Launch
- SutheDermal.com Launches: Revolutionizing Comfort in Self-Injection Therapies
- Local Commitment, National Expansion
- S2C and Andes Technology Announce FPGA-Based Prototyping Partnership to Accelerate Advanced RISC-V SoC Development
- CCHR Florida to Host a Veteran Advocates Networking Event
- Students Celebrate Earth Month and Learn About the Lifecycle of Trees
- Earth Day Gets Bloody in Brooklyn with Satirical Short Film: Don't Litter in Prospect Park!!
- DivsFeed.com Launches: Digital Magazine Spotlighting Human Integrity, Connection, and Impact
- Electives Appoints DraftKings' CPO Linda Aiello to Board Amid Record Quarter
- Blue Ocean Business School's Deputy Dean Delivers Keynote Address at India Blockchain Summit
- AdvisorVault's Consolidated 17a-4 D3P Service® Full Feature Set Available
- Most Common Car Accidents In America
- Kl Allen Issues A Fashion Industry "warning" With New Streetwear Couture Menswear Collection
- 810 Entertainment offers 'Graduation Party Packages' to SWFL seniors, families